Free Trial
ASX:BOD

Bod Science (BOD) Stock Price, News & Analysis

About Bod Science Stock (ASX:BOD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$4.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint pain and stiffness, joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia, as well as contract manufacturing services. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.

Receive BOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bod Science and its competitors with MarketBeat's FREE daily newsletter.

BOD Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:BOD
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.95 million
Net Margins
-352.17%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.32 million
Price / Cash Flow
N/A
Book Value
A($0.03) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$4.26 million
Optionable
Not Optionable
Beta
1.46
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (ASX:BOD) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners